Cardiovascular, metabolic, and endocrine drugs

Somapacitan

Somapacitan (Sogroya) is Novo Nordisk's once-weekly, reversible albumin-binding human growth hormone analog for growth hormone deficiency in adults and children 2.5 years and older, FDA-approved August 28, 2020.

Sep 29, 2026

Somatostatin analog therapy

Somatostatin analog therapy uses long-lasting synthetic versions of the hormone somatostatin, such as octreotide and lanreotide, to control hormonal symptoms and slow tumor growth in acromegaly and neuroendocrine tumors.

Sorbinil

Sorbinil, a Pfizer aldose reductase inhibitor (hydantoin class) for diabetic complications; first ARI in clinical trials, failed efficacy in the Sorbinil Retinopathy Trial, withdrawn for hypersensitivity.

Sotagliflozin

Sotagliflozin, sold as INPEFA, is an oral drug inhibiting both SGLT2 and SGLT1, approved in the US in 2023 to lower cardiovascular death and heart failure hospitalization risk in adults.

Sotalol

Sotalol (Betapace, Sotylize) is a racemic Class II/III antiarrhythmic, beta-blocker and I_Kr blocker approved in the US in 1992 for ventricular arrhythmias and AF rhythm control, with QT-prolongation and torsades risk requiring monitored initiation.

Sotatercept

Sotatercept (Winrevair, ACE-011) is a first-in-class activin signaling inhibitor, a fusion protein approved in the United States in March 2024 to improve exercise capacity in pulmonary arterial hypertension.

Spirapril

Spirapril (Renormax, SCH-33844) is a non-sulfhydryl ACE inhibitor prodrug hydrolyzed to active spiraprilat; 50% oral bioavailability, dual renal-hepatic elimination, 6 mg once daily for hypertension; FDA-approved 1994, discontinued in North America.

Spironolactone

Spironolactone (Aldactone) is a steroidal mineralocorticoid receptor antagonist and potassium-sparing diuretic discovered at Searle in the 1950s, launched 1960, used for edema, hypertension, heart failure, and PCOS, with hyperkalemia and gynecomastia as key risks.

SRSD107

SRSD107: investigational long-acting GalNAc siRNA by Sirius Therapeutics (靖因药业) targeting factor XI mRNA for anticoagulation; Phase 2 VTE and CAD/PAD trials, co-developed with CRISPR Therapeutics.

SRSD216

SRSD216 is an investigational Lp(a)-lowering siRNA from Sirius Therapeutics targeting LPA mRNA; Phase 1 single doses cut Lp(a) up to 94.7% with effects lasting over seven months.

Statin

Statin: HMG-CoA reductase inhibitor lowering LDL cholesterol; first statin mevastatin from Penicillium citrinum (Endo, 1970s), lovastatin FDA-approved 1987; first-line therapy for ASCVD prevention per 2026 ACC/AHA dyslipidemia guideline.

Streptokinase (drug)

Streptokinase, a 47 kDa protein from beta-hemolytic streptococci (S. equisimilis H46A), is the first plasminogen-activator thrombolytic drug, discovered by Tillett in 1933, dosed at 1.5 million IU IV, and still the low-cost (~US$200) clot-buster of developing countries.

Oct 15, 2026

Strophanthin

Strophanthin is a family of steroidal cardiac glycosides extracted from Strophanthus vine seeds, historically used as injectable drugs for heart failure and including ouabain, still used in the laboratory to inhibit the sodium pump.

Succinobucol

Succinobucol (AGI-1067), a monosuccinate ester of probucol developed by AtheroGenics, is an antioxidant anti-inflammatory drug candidate for atherosclerosis that reached Phase 3 (ARISE) without approval.

Sudi insulin

Sudi insulin (舒地胰岛素, insulin sudelidec, INS068, brand Rihengying) is Hengrui's long-acting basal insulin analog for adult type 2 diabetes; NMPA-approved 28 July 2026 as China's first independently developed long-acting insulin analog, non-inferior to glargine with lower nocturnal hypoglycemia.

Suloctidil

Suloctidil (Sulocton, Duolcitil), a peripheral vasodilator and antiplatelet propanolamine drug introduced in 1975 for arterial disease and withdrawn worldwide in the mid-1980s after hepatitis deaths.

Sulodexide

Sulodexide (Vessel, KRX-101) is an orally active glycosaminoglycan drug, 80% fast-moving heparin and 20% dermatan sulfate, used for venous thromboembolism prevention, chronic venous disease, and peripheral arterial disease.

Survodutide

Survodutide (BI 456906) is an investigational once-weekly injectable drug by Boehringer Ingelheim that acts on glucagon and GLP-1 receptors for obesity, type 2 diabetes, and MASH.

SYH2068

SYH2068 is CSPC Pharmaceutical Group's GalNAc-conjugated double-stranded siRNA injection targeting lipoprotein(a) for hyperlipoproteinemia(a); NMPA-approved April 2025, in Phase 1/2 trials in China (NCT07640217).

SYH2082

SYH2082 is CSPC Pharmaceutical's long-acting GLP1R/GIPR dual-agonist peptide for once-monthly injectable obesity treatment using the LiquidGel platform; licensed to AstraZeneca in January 2026 for up to $18.5 billion, now in Phase I.

SYH2086, oral small-molecule GLP-1 receptor agonist

SYH2086 (MGL-2086) is CSPC Pharmaceutical Group's preclinical oral small-molecule GLP-1 receptor agonist, an orforglipron derivative licensed globally to Madrigal Pharmaceuticals in July 2025 for up to US$2.075 billion for MASH combination therapy.

Tafluprost

Tafluprost (AFP-168; brand ZIOPTAN) is a preservative-free fluorinated prostaglandin F2α analogue eye drop, 0.0015%, approved in 2012 to lower intraocular pressure in open-angle glaucoma and ocular hypertension via FP receptor agonism.

Taliglucerase alfa

Taliglucerase alfa (Elelyso, Uplyso, prGCD) is a carrot-cell expressed recombinant glucocerebrosidase, the first FDA-approved plant-derived biologic (May 1, 2012), enzyme replacement therapy for type 1 Gaucher disease; refused EU authorization.

Tamsulosin

Tamsulosin, marketed as Flomax and generics, is a selective alpha-1 adrenoceptor antagonist used to treat benign prostatic hyperplasia, an enlargement of the prostate obstructing urine flow.

Taranabant

Taranabant (MK-0364) is a Merck cannabinoid-1 receptor inverse agonist for obesity; it produced significant weight loss but dose-related psychiatric and gastrointestinal adverse events, and its Phase III development was discontinued in October 2008.

Taspoglutide

Taspoglutide (BIM-51077, R-1583), a once-weekly GLP-1 receptor agonist from Ipsen licensed to Roche for type 2 diabetes; effective in T-emerge phase 3 trials but abandoned in 2010 over GI intolerance, antibodies, and anaphylaxis.

Tecarfarin

Tecarfarin (ATI-5923), an investigational oral vitamin K antagonist anticoagulant inhibiting VKORC1 like warfarin but metabolized by carboxylesterases instead of CYP450; phase 3, not approved.

Tedisamil

Tedisamil (KC-8857), a class III antiarrhythmic potassium channel blocker developed as a bradycardic agent; intravenous tedisamil converts recent-onset atrial fibrillation to sinus rhythm in about half of patients, with torsade de pointes as the main risk.

Telcagepant

Telcagepant (MK-0974) was Merck's first oral CGRP receptor antagonist (gepant) for acute migraine, with efficacy comparable to zolmitriptan but no vasoconstriction; development was discontinued in 2011 over hepatotoxicity in daily-dosing prophylaxis trials.